Back to search

Ireland· IE-PA-EU/1/24/1874/002

Hympavzi 150 mg solution for injection in pre-filled pen

A antihemorrhagics product containing marstacimab, registered in Ireland by Pfizer Europe MA EEIG. The same ATC class is registered in 2 of our 19 countries.

ATC B02

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedHympavzi 150 mg solution for injectio…ATCB02REGISTER NO.IE-PA-EU/1/24/1874/002PACKS LISTED1CHECKEDJuly 13, 2026

Where it is registered

Marstacimab is registered in 2 of 19 countries.

Countries holding a registration under ATC B02 (antihemorrhagics), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)

Marstacimab · ATC B02

2 / 19 countries

  • Ireland
  • Netherlands
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)
Active substance
Marstacimab
Manufacturer
Pfizer Europe MA EEIG
Country
Ireland (IE)
ATC code
B02
ATC class
ANTIHEMORRHAGICS
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
July 13, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/24/1874/002

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Marstacimab in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All marstacimab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Hympavzi
  • Liechtenstein · Hympavzi
  • Norway · Hympavzi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c29b36cd-4fe8-4e4d-91be-3fefd709e32f
GET /v1/drugs/c29b36cd-4fe8-4e4d-91be-3fefd709e32f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection in pre-filled pen",
  "routes": [
    "Subcutaneous use"
  ],
  "source": "hpra",
  "atc_all": [
    "B02"
  ],
  "strength": null,
  "pa_number": "EU/1/24/1874/002",
  "substances": [
    "Marstacimab"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": null,
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about marstacimab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.